GSK's Blenrep Approved in China for Relapsed/Refractory Multiple Myeloma
GSK sits 65% above its 52-week low of $35.08.
Summary
GSK announced that its oncology drug, Blenrep, has received approval from China's NMPA for treating relapsed or refractory multiple myeloma, expanding its global market presence.
Key Events · Product Development and Regulatory · GSK
-
China NMPA Approval
Blenrep (belantamab mafodotin) has been approved by China's National Medical Products Administration (NMPA) for the treatment of adults with 2L+ relapsed or refractory multiple myeloma in combination with bortezomib and dexamethasone (BVd).
-
Strong Clinical Data
The approval is supported by pivotal DREAMM-7 phase III trial data, which showed a 42% reduction in the risk of death and nearly tripled median progression-free survival compared to a daratumumab-based triplet.
-
Significant Market Expansion
This approval opens a substantial new market in China, where the incidence of multiple myeloma has doubled to approximately 30,000 new cases annually.
-
Differentiated Therapy
Blenrep is highlighted as the only anti-BCMA approved in 2L+ multiple myeloma in China and the only fully outpatient anti-BCMA therapy, minimizing patient and healthcare burden.
Analysis · GSK · Life Sciences
This approval in China for Blenrep (belantamab mafodotin) is a significant positive development for GSK, opening a substantial new market for a key oncology product. Multiple myeloma incidence in China is growing, and Blenrep offers a differentiated, outpatient anti-BCMA therapy with strong clinical data, including a 42% reduction in the risk of death and nearly tripled progression-free survival in the DREAMM-7 trial. This expands GSK's footprint in a critical therapeutic area and geographic region.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GSK was trading at $57.75 on NYSE in the Life Sciences sector, with a market capitalization of approximately $115.7B. The 52-week trading range was $35.08 to $61.70. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.